Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-21

Clinical Trial Update: A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) [Phase 2]

View source ↗

Summary

Phase 2 PK and safety study of nemolizumab in adolescents with atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2023-04-21